Loading clinical trials...
Loading clinical trials...
A Multicenter Phase 2 Open-Label, Single-Arm, Prospective, Interventional Study of Plasma-Derived Factor VIII/VWF (Alphanate®) in Immune Tolerance Induction Therapy in Subjects With Congenital Hemophilia A
Conditions
Interventions
Alphanate
Locations
20
United States
Emory University
Atlanta, Georgia, United States
University of Kentucky
Lexington, Kentucky, United States
Childrens Hospital and Clinics of Minnesota
Minneapolis, Minnesota, United States
The Childrens Mercy Hospital
Kansas City, Missouri, United States
Robert Wood Johnson Medical Group
New Brunswick, New Jersey, United States
Newark Beth Israel Medical Center & Children's Hospital of New Jersey
Newark, New Jersey, United States
Start Date
January 3, 2018
Primary Completion Date
September 18, 2020
Completion Date
September 18, 2020
Last Updated
November 23, 2021
Lead Sponsor
Grifols Therapeutics LLC
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions